ClinicalTrials.gg
CompletedNCT01094886Updated Mar 17, 2017Results posted

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

A Phase 3 interventional study of Rivaroxaban in Arthritis, Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-03-17.

Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Arthritis by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Arthritis · Johnson & Johnson.

Started
2010
the only one that year
Phase 3
3 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Arthritis by Johnson & Johnson, this one is the only one that started in 2010, is one of 3 in phase 3, and was the 9th registered.

Arthritis

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

Browse Arthritis studies →

Open to participants now

None of the 11 studies in Arthritis by Johnson & Johnson is open now. The open studies under Arthritis, anywhere →

Who these studies take

Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis by Johnson & Johnson as a file.
02

Study summary

The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in the veins after elective total hip or total knee replacement surgery. After providing written informed consent, screening procedures will be completed to assess eligibility. After enrollment, all patients will be switched from enoxaparin to rivaroxaban. Blood samples for the short-term effects of rivaroxaban will be taken at various times while in the subacute unit. At the time of discharge, if the study doctor feels it is appropriate, an adequate supply of rivaroxaban will be provided to complete the full course of therapy. Upon completion of rivaroxaban therapy, all patients will be required to have final study procedures performed. Safety evaluations at the final visit will include clinical blood laboratory tests, a physical examination, urine pregnancy test (if applicable), recording of any adverse events including details regarding any bleeding episodes or blood clot events, and assessment of the surgical wound. All patients will return any unused study medication and study participation will be complete.

Read the detailed description

The study medication, rivaroxaban, is an oral (by mouth) medication. Rivaroxaban directly inhibits one of the clotting mechanisms in the blood that is involved in the formation of blood clots in the veins in the body. The ability to inhibit blood clotting will be measured. Rivaroxaban is currently approved in the European Union by the European Medicines Agency (EMEA) for the prevention of blood clots in veins in orthopedic (bone) surgical patients who have had elective total joint (hip or knee) replacement. It is currently under review by the Food and Drug Administration (FDA) in the United States for this same indication. Enoxaparin is a medication that is injected into the fat tissue under the skin and is approved by the FDA for the treatment and prevention of blood clot formation in the veins. The goal of the study is to describe the short-term effects that the study drug has on the body when a patient is switched from enoxaparin to rivaroxaban. The study hypothesis, or theory, is that when switched from enoxaparin to rivaroxaban the ability of the body to inhibit blood clotting activity will continue. This is an open-label study which means that all persons involved in the study will know what study drug is being given to them. It is a single-arm study which means that all patients will be administered the same study medication, rivaroxaban. The study will be conducted at large orthopedic centers in the United States. All patients will have had elective total hip or total knee replacement surgery. While in the hospital, eligible patients will have been receiving enoxaparin either 30 mg twice a day or 40 mg once daily. Upon discharge from the hospital all eligible patients will require a stay in a subacute unit and continuing medication for blood clot prevention. After providing written informed consent, patients will have screening procedures completed to determine eligibility. Safety evaluations at the screening procedure will include a physical examination, vital signs, and clinical blood laboratory tests. Women, who are able to bear children, will also have a screening blood pregnancy test performed. A negative pregnancy test is needed to be in the study. Just before receiving the first dose of rivaroxaban, 10 mg, blood sampling for the short-term effects of rivaroxaban will begin and continue at various times. All patients will receive 10 mg of rivaroxaban daily. In addition, the study doctor will do an assessment of the surgical wound. At the time of discharge from the subacute unit, if the study doctor feels it is appropriate, an adequate supply of rivaroxaban will be provided to complete the full course of therapy. If a patient withdraws his/her consent prior to completion of the study, the appropriate course of blood clot prevention therapy will be prescribed by the study doctor. Upon completion of rivaroxaban therapy, all patients will be required to have final study procedures performed. Those patients who continue oral rivaroxaban after discharge from the subacute unit will be required to return for an office visit for final study procedures either at the time of completion of rivaroxaban therapy or at the surgical follow-up visit. Patients who have rivaroxaban discontinued prior to discharge from the subacute unit will have final study procedures completed at that time and a subsequent office visit will not be required. In all cases, the prescribed rivaroxaban therapy must have been completed prior to the time of the final visit. Safety evaluations at the final visit will include clinical laboratory blood tests, a physical examination, urine pregnancy test (if applicable), recording of any adverse events including details regarding any bleeding episodes or blood clot events, and assessment of the surgical wound. All patients will return any unused study medication and study participation will be complete. All patients will receive oral rivaroxaban 10mg daily. First dose of rivaroxaban will be given within 2 days after admission to the subacute unit, in the morning within 12 hrs (if 30mg twice a day) or 24 hours (if 40mg daily) of the enoxaparin dose. Patients will then continue to receive a daily 10 mg dose each morning. The total duration of combined therapy (enoxparin plus rivaroxaban) may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement.

03

Conditions studied

  • Arthritis
  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
  • Thromboembolism

Keywords

  • Total Hip Replacement
  • Total Knee Replacement
  • Hip Implant
  • Knee Implant
  • Joint Prosthesis
  • Orthopedic Surgery
  • Rivaroxaban
  • Xarelto
  • Blood Clot
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergone elective total hip or knee replacement surgery
  • Received postoperative venous blood clot prevention therapy within 24 hours of the surgery
  • Currently prescribed enoxaparin 30mg subcutaneous (SQ) twice a day or 40mg SQ daily for venous blood clotting prevention with an expected duration of continued prevention therapy of at least 3 days after admission to a subacute unit
  • Discharged from the hospital to a subacute unit (including skilled nursing facilities and rehabilitation units) and committed to remaining in the unit for the duration of the Pharmacodynamic blood sampling period of the study

Exclusion criteria

Exclusion Criteria:

  • count \<90,000/µL based on screening laboratory assessments
  • active internal bleeding or high risk of bleeding
  • history of, or condition associated with, increased bleeding risk including
  • planned invasive procedure with potential for uncontrolled bleeding, including major surgery
  • sustained uncontrolled high blood pressure, defined as systolic blood pressure =180 mmHg or diastolic blood pressure =100 mmHg
  • kidney disease and/or impaired kidney function
  • clinically significant liver disease
  • anemia
  • known allergies, , or intolerance to rivaroxaban
  • indication for anticoagulant (blood thinning) therapy for a condition other than blood clot prevention
  • anticipated need for treatment with a prescription or nonprescription non-steroidal anti-inflammatory drugs (NSAIDs)
  • any patient who has taken more than one or two doses of aspirin (>100 mg/dose) in the week prior to enrollment will not be allowed to participate
  • Drug addiction or alcohol abuse within 3 years prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    001

    Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement

    Drug: Rivaroxaban

Interventions

  • 10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement

06

What researchers measure

Primary outcomes

  1. Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)

    Descriptive statistics for per-patient maximum Anti-Factor Xa laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3

    Time frame: Day 1, Day 3

  2. Summary of Change From Day 3 to Day 1 in Maximum Prothrombin Time

    Descriptive statistics for per-patient maximum prothrombin time laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3

    Time frame: Day 1, Day 3

Secondary outcomes

  1. Summary of Change From Day 1 to Day 3 in Area Under the Curve (AUC) of aFXa

    Descriptive statistics for Area Under the Curve (AUC) on Study Day 1 and Day 3 for Anti-Factor Xa, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose

    Time frame: Day 1, Day 3

  2. Summary of Change From Day 1 to Day 3 in AUC of Prothrombin Time

    Descriptive statistics for AUC on Study Day 1 and Day 3 for prothrombin time, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose

    Time frame: Day 1, Day 3

07

Results

Posted Feb 27, 2012
Limitations and caveats
There were 56 subjects enrolled in the study, but only 53 of them were treated with study medication.

Participant flow

Participant flow — Overall Study
MilestoneRivaroxaban
Started53
Completed46
Not completed7
Withdrew: Adverse event2
Withdrew: Withdrawal by subject5

Outcome measures

PrimarySummary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)

Descriptive statistics for per-patient maximum Anti-Factor Xa laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3

Time frame:
Day 1, Day 3
Reported as:
Mean · IU/ml
Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)
IU/mlRivaroxaban
Day 11.66 ± 0.422
Day 31.83 ± 0.305
Statistical analysis
  • Rivaroxaban · t-test, 2 sided · p = .008 · Mean difference (final values): 0.20 · 95% CI -0.05 to 0.34
PrimarySummary of Change From Day 3 to Day 1 in Maximum Prothrombin Time

Descriptive statistics for per-patient maximum prothrombin time laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3

Time frame:
Day 1, Day 3
Reported as:
Mean · sec
Summary of Change From Day 3 to Day 1 in Maximum Prothrombin Time
secRivaroxaban
Day 121.57 ± 3.405
Day 320.51 ± 3.179
Statistical analysis
  • Rivaroxaban · t-test, 2 sided · p = 0.111 · Mean difference (final values): -0.91 · 95% CI -2.048 to 0.219
SecondarySummary of Change From Day 1 to Day 3 in Area Under the Curve (AUC) of aFXa

Descriptive statistics for Area Under the Curve (AUC) on Study Day 1 and Day 3 for Anti-Factor Xa, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose

Time frame:
Day 1, Day 3
Reported as:
Mean · IU/ml*hour
Summary of Change From Day 1 to Day 3 in Area Under the Curve (AUC) of aFXa
IU/ml*hourRivaroxaban
Day 121.35 ± 7.086
Day 320.74 ± 7.17
Statistical analysis
  • Rivaroxaban · t-test, 2 sided · p = 0.87 · Mean difference (final values): -0.21 · 95% CI -2.77 to 2.35
SecondarySummary of Change From Day 1 to Day 3 in AUC of Prothrombin Time

Descriptive statistics for AUC on Study Day 1 and Day 3 for prothrombin time, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose

Time frame:
Day 1, Day 3
Reported as:
Mean · sec*hour
Summary of Change From Day 1 to Day 3 in AUC of Prothrombin Time
sec*hourRivaroxaban
Day 1420.46 ± 44.361
Day 3391.37 ± 42.664
Statistical analysis
  • Rivaroxaban · t-test, 2 sided · p = <0.001 · Mean difference (final values): -35.13 · 95% CI -48.01 to -22.26

Adverse events

Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban—3/53 (5.7%)38/53 (71.7%)
Most frequent serious events
Most frequent serious events
EventRivaroxaban
Arthritis InfectiveInfections and infestations1/53
Lumbar Vertebral FractureInjury, poisoning and procedural complications1/53
AnxietyPsychiatric disorders1/53
Most frequent other events
Most frequent other events
EventRivaroxaban
ConstipationGastrointestinal disorders12/53
NauseaGastrointestinal disorders9/53
AstheniaGeneral disorders7/53
PyrexiaGeneral disorders7/53
Blood Iron DecreasedInvestigations5/53
Muscle SpasmsMusculoskeletal and connective tissue disorders5/53
InsomniaPsychiatric disorders5/53
OedemaGeneral disorders4/53
FallInjury, poisoning and procedural complications3/53
TransfusionSurgical and medical procedures3/53

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rivaroxaban
<=18 years0
Between 18 and 65 years12
>=65 years41
Age, Continuous
Age, Continuous(years)Rivaroxaban
Mean70.5 ± 11.14
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban
Female29
Male24
Region of Enrollment
Region of Enrollment(participants)Rivaroxaban
UNITED STATES53
Surgical Type
Surgical Type(participants)Rivaroxaban
Hip26
Knee27
Baseline BMI
Baseline BMI(kg/m^2)Rivaroxaban
Mean29.5 ± 6.78
Baseline Estimated Glomerular Filtration Rate (eGFR) From Local Lab
Baseline Estimated Glomerular Filtration Rate (eGFR) From Local Lab(participants)Rivaroxaban
eGFR >= 60 mL/min47
eGFR Between 30 and 59 mL/min6
Ethnicity
Ethnicity(participants)Rivaroxaban
Hispanic or Latino1
Not Hispanic or Latino52
08

Study locations

5 sites
  • Denver, Colorado, United States
  • Hollywood, Florida, United States
  • Tamarac, Florida, United States
  • Vero Beach, Florida, United States
  • Glen Cove, New York, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2010
First posted
Mar 29, 2010
Start
Mar 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Feb 27, 2012
Last update
Mar 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01094886
Collaborators
Bayer
Responsible party
Sponsor
First posted
Mar 29, 2010
Start date
Mar 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Feb 27, 2012
Last update
Mar 17, 2017

Study contacts

Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial
study director · Ortho-McNeil Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion